Medicure Announces Positive Settlement of Product Development and Supply Contracts
Medicure has announced a successful settlement of product development and supply contracts between its subsidiaries Medicure International Inc. & Medicure Pharma Inc. and an undisclosed third party. The company has received a €1.5 million settlement payment as part of the final agreement. The remaining terms of the settlement and the identity of the third party remain confidential.
Medicure ha annunciato un accordo di successo riguardante contratti di sviluppo prodotto e fornitura tra le sue filiali Medicure International Inc. e Medicure Pharma Inc. e una terza parte non divulgata. L'azienda ha ricevuto un pagamento di 1,5 milioni di euro come parte dell'accordo finale. I termini rimanenti dell'accordo e l'identità della terza parte rimangono riservati.
Medicure ha anunciado un acuerdo exitoso sobre contratos de desarrollo de productos y suministro entre sus subsidiarias Medicure International Inc. y Medicure Pharma Inc. y una tercera parte no divulgada. La compañía ha recibido un pago de 1,5 millones de euros como parte del acuerdo final. Los términos restantes del acuerdo y la identidad de la tercera parte permanecen confidenciales.
메디큐어는 자회사 메디큐어 인터내셔널 Inc. 및 메디큐어 제약 Inc.와 공개되지 않은 제3자 간의 제품 개발 및 공급 계약의 성공적인 합의를 발표했습니다. 회사는 최종합의의 일환으로 150만 유로의 합의금을 받았습니다. 합의의 나머지 조건과 제3자의 신원은 비밀로 유지됩니다.
Medicure a annoncé un règlement réussi des contrats de développement de produits et de fourniture entre ses filiales Medicure International Inc. et Medicure Pharma Inc. et une troisième partie non divulguée. L'entreprise a reçu un paiement de 1,5 million d'euros dans le cadre de l'accord final. Les autres termes du règlement et l'identité de la troisième partie restent confidentiels.
Medicure hat eine erfolgreiche Einigung über Produktentwicklungs- und Lieferverträge zwischen ihren Tochtergesellschaften Medicure International Inc. und Medicure Pharma Inc. sowie einer nicht genannten dritten Partei bekannt gegeben. Das Unternehmen hat im Rahmen der endgültigen Vereinbarung eine Zahlung von 1,5 Millionen Euro erhalten. Die verbleibenden Bedingungen der Einigung sowie die Identität der dritten Partei bleiben vertraulich.
- Received €1.5 million settlement payment, improving cash position
- None.
WINNIPEG, MB / ACCESSWIRE / October 24, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, announced today that a product development and supply contract settlement between its subsidiaries Medicure International Inc. & Medicure Pharma Inc., and a third party has been reached.
Medicure has received a payment of € 1.5 million as final settlement. All other terms of the settlement along with the name of the party involved remain confidential.
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAG® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley Drug"), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug® is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT®, please visit www.aggrastathdb.com or refer to the full Prescribing Information. For additional information about ZYPITAMAG®, please visit www.zypitamag.com or refer to the full Prescribing Information.
To be added to Medicure's e-mail list, please visit: http://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a priority review voucher from the United State Food and Drug Administration, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its current Form 20F.
AGGRASTAT® (tirofiban hydrochloride) injection, ZYPITAMAG® (pitavastatin) tablets, and Marley Drug® are registered trademarks.
For more information, please contact:
Dr. Albert D. Friesen
Chief Executive Officer
Tel. 888-435-2220
Fax 204-488-9823
E-mail: info@medicure.com
www.medicure.com
SOURCE: Medicure, Inc.
View the original press release on accesswire.com
FAQ
How much did Medicure (MCUJF) receive in the October 2024 contract settlement?
Which Medicure subsidiaries were involved in the 2024 contract settlement?
What was disclosed about the third party in Medicure's October 2024 settlement?
